NVAX

NVAX

USD

Novavax Inc. Common Stock

$7.510-0.175 (-2.277%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$7.685

Máximo

$7.860

Mínimo

$7.500

Volume

5.04M

Fundamentos da empresa

Capitalização de mercado

1.2B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

6.00M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $5.01Atual $7.510Máximo $11.55

Notícias relacionadas

Analyst Upgrades

TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7

TD Cowen analyst Brendan Smith maintains Novavax with a Hold and lowers the price target from $8 to $7.

Ver mais
TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7
PR Newswire

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling...

Ver mais
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Analyst Upgrades

Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax with a Overweight rating and announces Price Target of $18.

Ver mais
Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11

HC Wainwright & Co. analyst Sean Lee maintains Novavax with a Buy and raises the price target from $10 to $11.

Ver mais
HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11
PR Newswire

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model by...

Ver mais
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.